DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Clinical Lung Cancer

• Publication date

  2009-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3816/CLC.2009.n.015PMID 19362955
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• DNA Repair by ERCC1 in Non-Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy

  2010cited by this paper
• Prospective Assessment of XPD Lys751Gln and XRCC1 Arg399Gln Single Nucleotide Polymorphisms in Lung Cancer

  2007cited by this paper
• Genetic polymorphisms and treatment response in advanced non-small cell lung cancer.

  2007cited by this paper
• ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.

  2007cited by this paper
• Conformational Effects of a Common Codon 399 Polymorphism on the BRCT1 Domain of the XRCC1 Protein

  2007cited by this paper
• Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum‐based chemotherapy in advanced nonsmall cell lung cancer

  2006cited by this paper
• Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients.

  2006cited by this paper
• ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.

  2006cited by this paper
• DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

  2006cited by this paper
• Regulation of DNA repair gene expression in human cancer cell lines

  2006cited by this paper
• Glutathione-S-Transferase P1 Isoenzyme Polymorphisms, Platinum-Based Chemotherapy, and Non-small Cell Lung Cancer

  2006cited by this paper
• DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.

  2006cited by this paper
• The treatment of advanced non-small cell lung cancer

  2005cited by this paper
• Polymorphisms in ERCC1 and Grade 3 or 4 Toxicity in Non–Small Cell Lung Cancer Patients

  2005cited by this paper
• Gene-Smoking Interaction Associations for the ERCC1 Polymorphisms in the Risk of Lung Cancer

  2005cited by this paper
• ERCC2 /XPD gene polymorphisms and lung cancer: a HuGE review.

  2005cited by this paper
• Excision Repair Cross-Complementation Group 1 Polymorphism Predicts Overall Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy

  2004cited by this paper
• XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.

  2004cited by this paper
• Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.

  2004cited by this paper
• Molecular predictors of response to chemotherapy in lung cancer.

  2004cited by this paper
• Reversal of cisplatin and multidrug resistance by ribozyme-mediated glutathione suppression

  2003cited by this paper
• LDA - a java-based linkage disequilibrium analyzer

  2003cited by this paper
• Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

  2002cited by this paper
• Significance of Nuclear Glutathione S‐Transferase π in Resistance to Anti‐cancer Drugs

  2002cited by this paper
• Glutathione content is correlated with the sensitivity of lines of PC12 cells to cisplatin without a corresponding change in the accumulation of platinum

  2001cited by this paper
• A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer.

  2001cited by this paper
• Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.

  2001cited by this paper
• Reversal of cisplatin and multidrug resistance by ribozyme-mediated glutathione suppression.

  2001cited by this paper
• Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells.

  2000cited by this paper
• ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells

  2000cited by this paper
• Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.

  2000cited by this paper
• XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency.

  1999cited by this paper
• Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans.

  1998cited by this paper
• Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution.

  1998cited by this paper
• A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues.

  1997cited by this paper
• The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance.

  1995cited by this paper
• Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties.

  1994cited by this paper
• Codon usage can affect efficiency of translation of genes in Escherichia coli.

  1984cited by this paper
• Polymorphisms in the Dna Repair Genes Xrcc1 and Ercc2 and Biomarkers of Dna Damage in Human Blood Mononuclear Cells Cross-complementing Group 1) than in 399arg/arg Carriers of Breaks following Base Excision Repair (ber) Resulting From

  year unknowncited by this paper

• Genetic Navigation: A Narrative Review of XRCC1 Polymorphism Impact on Platinum-Based Chemotherapy Outcomes in NSCLC Patients

  2025cites this paper
• Impact of the deletion glutathione S-transferase (class Mu) on lung cancer risk among smokers

  2024cites this paper
• Genotyping, in silico screening and molecular dynamics simulation of SNPs of MGMT and ERCC1 gene in lung cancer patients treated with platinum-based doublet chemotherapy

  2023cites this paper
• The XRCC1 and TP53 gene polymorphisms are associated with advanced-stage disease and early distant metastasis at diagnosis in non-small cell lung cancer

  2023cites this paper
• Germline mutations in high penetrance genes are associated with worse clinical outcomes in patients with non–small cell lung cancer

  2022cites this paper
• Application of gene polymorphisms to predict the sensitivity of patients with locally advanced non-small cell lung cancer undergoing chemoradiotherapy.

  2021cites this paper
• GSTP1 Ile 105 Val polymorphism among North Indian lung cancer patients treated using monotherapy and poly-pharmacy

  2021cites this paper
• Genetic polymorphisms of GSTP1, XRCC1, XPC and ERCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer patients of Bangladesh

  2020cites this paper
• ERCC1 and XRCC1 single nucleotide polymorphisms can guide treatment decision in patients with metastatic non-small cell lung cancer

  2020cites this paper
• Polymorphisms in the BER and NER pathways and their influence on survival and toxicity in never-smokers with lung cancer

  2020cites this paper
• Pharmacogenetic Association between XRCC1 Polymorphisms and Response to Platinum-Based Chemotherapy in Asian Patients with NSCLC: A Meta-Analysis

  2020cites this paper
• Evolving insights: how DNA repair pathways impact cancer evolution

  2020cites this paper
• Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients

  2019cites this paper
• Clinical research of individualized therapy in advanced esophageal cancer based on the ERCC1 C8092A genotype.

  2018cites this paper
• Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer

  2018cites this paper
• Relationship between clinical toxicities and ERCC1 rs3212986 and XRCC3 rs861539 polymorphisms in cervical cancer patients

  2018cites this paper
• Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1

  2018cites this paper
• Glutathione S-Transferase Gene Polymorphisms are Associated with an Improved Treatment Response to Cisplatin-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC): A Meta-Analysis

  2018influential citation
• Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis

  2017cites this paper
• Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy: a meta-analysis based on the PRISMA statement

  2017cites this paper
• Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer.

  2017cites this paper
• Association of DNA repair gene polymorphisms with the risk of radiation pneumonitis in lung cancer patients

  2017cites this paper
• Deletion of GSTM1 and GSTT1 Genes and Lung Cancer Survival: a Systematic Review

  2017influential citation
• Predictive assessment in pharmacogenetics of Glutathione S-transferases genes on efficacy of platinum-based chemotherapy in non-small cell lung cancer patients

  2017cites this paper
• Evaluation of Prediction of Polymorphisms of DNA Repair Genes on the Efficacy of Platinum‐Based Chemotherapy in Patients With Non‐Small Cell Lung Cancer: A Network Meta‐Analysis

  2017cites this paper
• Genetic Variations of DNA Repair Genes in Breast Cancer

  2017cites this paper
• Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.

  2017cites this paper
• Role of GSTM1, GSTT1, and GSTP1 IIe105Val gene polymorphisms in the response to chemotherapy and overall survival of advanced non-small cell lung cancer.

  2016cites this paper
• DNA Repair Gene Polymorphisms in Non-Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Containing Chemotherapy

  2016cites this paper
• ERCC1 C118T polymorphism has predictive value for platinum-based chemotherapy in patients with late-stage bladder cancer.

  2016cites this paper
• Pharmacogenomics in Pediatric Oncology: Review of Gene—Drug Associations for Clinical Use

  2016cites this paper
• Pharmacogenomics of platinum-based chemotherapy response in NSCLC: a genotyping study and a pooled analysis

  2016influential citation
• An investigation of the pharmacogenetic basis of toxicity to platinum chemotherapy agents

  2016cites this paper
• A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-Analysis

  2016influential citation
• The success of stem cell transplantations and the potential post-transplantation complications may be dependent, among other factors, on the capacity of the recipient and the transplanted cells to repair DNA damage

  2016cites this paper
• Role of GSTM 1 , GSTT 1 , and GSTP 1 IIe 105 Val gene polymorphisms in the response to chemotherapy and overall survival of advanced non-small cell lung cancer

  2016influential citation
• Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients.

  2016cites this paper
• Analyzing the association between XRCC1 c.1804C>A genetic variant and lung cancer susceptibility in the Chinese population.

  2016cites this paper
• ERCC1 and XRCC1 but not XPA single nucleotide polymorphisms correlate with response to chemotherapy in endometrial carcinoma

  2016cites this paper
• A meta-analysis identifies ERCC1 gene polymorphism as a predictor of better patient response to treatment with radiochemotherapy

  2016cites this paper
• XPD c.934G>A polymorphism of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation

  2016influential citation
• Glutathione S-transferase pi polymorphism contributes to the treatment outcomes of advanced non-small cell lung cancer patients in a Chinese population.

  2016cites this paper
• Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer?

  2016cites this paper
• Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine.

  2016cites this paper
• Bronchial-pulmonary adenocarcinoma subtyping relates with different molecular pathways.

  2015cites this paper
• Predictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy

  2015cites this paper
• PI3K/PTEN/AKT/mTOR polymorphisms: Association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximab‐docetaxel

  2015cites this paper
• Use a survival model to correlate single-nucleotide polymorphisms of DNA repair genes with radiation dose-response in patients with non-small cell lung cancer.

  2015cites this paper
• Effect of X-ray repair cross complementing group 1 polymorphisms on the efficacy of platinum-based chemotherapy in patients with nonsmall cell lung cancer.

  2015cites this paper
• Role of GSTP1 Ile105Val and XRCC1 Arg194Trp, Arg280His and Arg399Gln gene polymorphisms in the clinical outcome of advanced non-small cell lung cancer.

  2015cites this paper
• Original Article Polymorphisms of co-inhibitory molecules (CTLA-4/PD-1/PD-L1) and the risk of non-small cell lung cancer in a Chinese population

  2015cites this paper
• Predictive potential role of GSTs gene polymorphisms in the treatment outcome of advanced non-small cell lung cancer patients.

  2015cites this paper
• DNA Repair Gene Polymorphisms in Relation to Non-Small Cell Lung Cancer Survival

  2015cites this paper
• XRCC1 genetic polymorphisms and sensitivity to platinum-based drugs in non-small cell lung cancer: an update meta-analysis based on 4708 subjects.

  2015cites this paper
• ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors

  2015cites this paper
• The influence of XRCC1 genetic variants on lung cancer susceptibility in Chinese Han population.

  2015cites this paper
• Polymorphisms of co-inhibitory molecules (CTLA-4/PD-1/PD-L1) and the risk of non-small cell lung cancer in a Chinese population.

  2015cites this paper
• ERCC1 SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy

  2015cites this paper
• Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?

  2014cites this paper
• RETRACTED ARTICLE: The association of c.1471G>A genetic polymorphism in XRCC1 gene with lung cancer susceptibility in Chinese Han population

  2014influential citation
• Inter-individual variation in DNA repair capacity: a need for multi-pathway functional assays to promote translational DNA repair research.

  2014cites this paper
• The association between the GSTP1 A313G and GSTM1 null/present polymorphisms and the treatment response of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients: a meta-analysis

  2014influential citation
• ERCC1 Cys8092Ala and XRCC1 Arg399Gln Polymorphisms Predict Progression-Free Survival after Curative Radiotherapy for Nasopharyngeal Carcinoma

  2014cites this paper
• What's your poison? Impact of individual repair capacity on the outcomes of genotoxic therapies in cancer. Part II – information content and validity of biomarkers for individual repair capacity in the assessment of outcomes of anticancer therapy

  2014cites this paper
• Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.

  2014cites this paper
• The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis

  2014influential citation
• Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinum-based chemotherapy in non-small cell lung cancer

  2014cites this paper
• Association of the XRCC1 c.1178G>A genetic polymorphism with lung cancer risk in Chinese.

  2014influential citation
• WITHDRAWN: Bronchial-pulmonary adenocarcinoma subtyping relates with different molecular pathways.

  2014cites this paper
• Polymorphisms in the XRCC1 gene are associated with treatment response to platinum chemotherapy in advanced non-small cell lung cancer patients based on meta-analysis.

  2014cites this paper
• The relationship between genetic variants of XRCC1 gene and lung cancer susceptibility in Chinese Han population

  2014influential citation
• Association of HMGB1 and HMGB2 genetic polymorphisms with lung cancer chemotherapy response

  2014cites this paper
• Role of XRCC 1 and ERCC 5 polymorphisms on clinical outcomes in advanced non-small cell lung cancer

  2014cites this paper
• Role of XRCC1 and ERCC5 polymorphisms on clinical outcomes in advanced non-small cell lung cancer.

  2014cites this paper
• Individual capacity for detoxification of genotoxic compounds and repair of DNA damage. Commonly used methods for assessment of capacity for DNA repair

  2014cites this paper
• Polymorphisms in the XRCC1 gene are associated with treatment response to platinum chemotherapy in advanced non-small cell lung cancer patients based on meta-analysis

  2014cites this paper
• Facteurs de résistance à la chimiothérapie à base de sels de platine dans les cancers bronchiques non à petites cellules : Rôle de la voie Sonic Hedgehog dans la chimiorésistance

  2014cites this paper
• Association between single nucleotide polymorphism of PD‐L1 gene and non‐small cell lung cancer susceptibility in a Chinese population

  2014cites this paper
• Lung cancer survival and deletion of GSTM1 and GSTT1 genes. A case-series from Spain.

  2013cites this paper
• Predictive Value of XPD Polymorphisms on Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

  2013cites this paper
• Predictive Effect of XPA and XPD Polymorphisms on Survival of Advanced NSCLC Patients Treated with Platinum-Based Chemotherapy: A Three-Dimensional (3-D), Polyacrylamide Gel-Based DNA Microarray Method

  2013cites this paper
• A pilot pharmacogenomics study examining the influence of cytotoxic and metabolising genetic polymorphisms on chemotherapy toxicity and outcome in osteosarcoma

  2013cites this paper
• Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.

  2013cites this paper
• Predicting toxicity in advanced lung cancer patients treated with platinum-based chemotherapy

  2013cites this paper
• Genetic polymorphisms of ERCC1‑118, XRCC1‑399 and GSTP1‑105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin‑based adjuvant chemotherapy.

  2013cites this paper
• ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin

  2013cites this paper
• Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population

  2013cites this paper
• DNA repair gene associated with clinical outcome of epithelial ovarian cancer treated with platinum-based chemotherapy.

  2013cites this paper
• Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer

  2013cites this paper
• Association between the c . 910 A > G genetic polymorphism in XRCC 1 gene and susceptibility to lung cancer in a Chinese population

  2013influential citation
• ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy

  2013cites this paper
• Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.

  2013cites this paper
• Mini Review: Relationship Between Platinum Induced Toxicities and Nucleotide Excision Repair (NER) Pathway Polymorphisms in Non-Small Cell Lung Cancer (NSCLC) Patients and Beyond

  2013cites this paper
• Platinum-Based Chemotherapy : A Three-Dimensional ( 3-D ) , Polyacrylamide Gel-Based DNA Microarray Predictive Effect of XPA and XPD Polymorphisms on Survival of Advanced NSCLC Patients Treated with

  2013cites this paper
• Lung cancer survival and deletion of GSTM1 and GSTT1 genes. A case-series from Spain

  2013cites this paper
• Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients.

  2013cites this paper
• Association between eIF3α polymorphism and severe toxicity caused by platinum‐based chemotherapy in non‐small cell lung cancer patients

  2013cites this paper
• Predictive value of ERCC 1 and RRM 1 gene single-nucleotide polymorphisms for first-line platinum-and gemcitabine-based chemotherapy in non-small cell lung cancer patients

  2013cites this paper
• Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.

  2013cites this paper
• Polymorphisms in XPD Gene Could Predict Clinical Outcome of Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer Patients: A Meta-Analysis of 24 Studies

  2013cites this paper